USFDA-Gujarat FDCA to meet to discuss GMP compliance, capacity building

"The state also has 3,533 allopathic manufacturing units and has issued 6.9 lakh product licenses to date," Gujarat FDCA Commissioner Dr. H G Koshia stated.

160
USFDA
Picture: Pixabay

Last Updated on December 7, 2022 by The Health Master

The USFDAGujarat Food and Drug Control Administration (FDCA) Bilateral Regulatory Forum will be held in the month of January 2023 for the US and Indian drug regulators to discuss compliance with Good Manufacturing Practices (GMPs) and capacity building, among other relevant subjects.

During the last USFDA-Gujarat FDCA Regulatory Forum meeting held virtually last year, Gujarat FDCA discussed plans to scale up the presence of more USFDA and WHO-GMP-compliant units in Gujarat towards enhancing the production of quality medicines for the benefit of patient safety and compliance.

The USFDA delegation will be led by Sarah McMullen, director of the Office of Global Policy and Strategy, USFDA, India Office (INO), New Delhi.

“The USFDA-Gujarat FDCA Regulatory Forum, which was started in 2008, is based on the premise of training, networking, knowledge sharing, and compliance.”

“This will also help Indian regulators in understanding regulatory requirements of the USFDA.”

“More so as Gujarat has 1081 WHO-GMP compliance units and around 140 USFDA approved drug manufacturing units in the country.”

“The state also has 3,533 allopathic manufacturing units and has issued 6.9 lakh product licenses to date,” Gujarat FDCA Commissioner Dr. H G Koshia stated.

The USFDA-Gujarat FDCA Regulatory Forum will also be instrumental in equipping Indian regulators and industry on good distribution practices (GDP) and good lab practices (GLP).

Last year, in the month of January, officials from Gujarat FDCA shared their experiences of the COVID-19 pandemic with USFDA officials on regulatory initiatives taken to scale up the accessibility of medicines and healthcare.

As a part of knowledge sharing, USFDA officials and Gujarat FDCA officials will also discuss the drug inspection lifecycle, which includes site selection, planning, execution, reporting, evaluation, regulatory action, and case study for future participation as an observer in the USFDA-led inspection.

A team of USFDA officials visited Gujarat FDCA in 2019, during which Letitia Robinson, country director, OIP, India Office, and USFDA comprehensively discussed building regulatory compliance in both the US and India.

CDSCO panel gives nod for Esomeprazole Dual Release Gastro resistant tablets

Drug recall: Dr. Reddy’s, Sun Pharma recall these drugs due to this reason

USFDA gives nod for Diclofenac Sodium topical solution

IPC releases amendment list for IP 2022, details here

NPPA releases 2nd list with draft ceiling prices for 43 formulations

USFDA gives approval for Venlafaxine ER tablets

Gujarat FDCA launches online licensing system for cosmetics

IPC to digitize Indian Pharmacopoeia (IP) soon

DCOIWA’s state-wise training program for drug regulators begins

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news